TG Therapeutics
TGTX
NASDAQ
IPO1995
about TGTX
TG Therapeutics is a biopharmaceutical company focused on developing innovative treatments for cancers such as lymphoma and leukemia, immune-mediated diseases like psoriasis, and other conditions, with key products including umilast, an oral disease-modifying therapy in late-stage development.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $30.55 | $31.09 | $29.86 | $4.8B | 1.96M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| +$2.69 | n/a | n/a | 18.16% | 241.73% | 0% |